Journal article
Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer
ER Thompson, SM Rowley, S Sawyer, DM Eccles, AH Trainer, G Mitchell, PA James, IG Campbell
Plos One | Published : 2013
Abstract
Mutations in RAD51D have been associated with an increased risk of hereditary ovarian cancer and although they have been observed in the context of breast and ovarian cancer families, the association with breast cancer is unclear. The aim of this current study was to validate the reported association of RAD51D with ovarian cancer and assess for an association with breast cancer. We screened for RAD51D mutations in BRCA1/2 mutation-negative index cases from 1,060 familial breast and/or ovarian cancer families (including 741 affected by breast cancer only) and in 245 unselected ovarian cancer cases. Exons containing novel non-synonymous variants were screened in 466 controls. Two overtly delet..
View full abstractGrants
Awarded by Cancer Australia (NBCF)
Awarded by NBCF (Priority-driven Collaborative Cancer Research Scheme grant)
Funding Acknowledgements
kConFab is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up study was funded between 2001-2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia (NBCF) (ID 628333). This study was supported by the Victorian Cancer Agency, Cancer Australia, and the NBCF (Priority-driven Collaborative Cancer Research Scheme grant, ID 628610), and the Wessex Cancer Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.